EQRx Investor Relations Material

EQRx, Inc. is a pharmaceutical company engaged in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases. Its pre-registratrial programs in Phase III clinical trials include Aumolertinib, an epidermal growth factor receptor (EGFR) inhibitor for the treatment of patients with EGFR-mutated non-small cell lung cancer (NSCLC); and Sugemalimab, an anti-programmed death-ligand 1 antibody for the treatment of Stage III and Stage IV NSCLC. Its other programs in pipeline include clinical and pre-clinical stage assets, which comprise Lerociclib, a small molecule cyclin-dependent kinase 4/6 inhibitor, which is in Phase II clinical trials in patients with metastatic breast cancer; EQ176 and EQ121 patents, both of which are in various Phase I trials as well.